Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.

JCI insight - 8 Sept 2021

Padhye Aparna, Konen Jessica M, Rodriguez B Leticia, Fradette Jared J, Ochieng Joshua K, Diao Lixia, Wang Jing, Lu Wei, Solis Luisa S, Batra Harsh, Raso Maria G, Peoples Michael D, Minelli Rosalba, Carugo Alessandro, Bristow Christopher A, Gibbons Don L

Abstract excerpt

Lack of sustained response to therapeutic agents in patients with KRAS-mutant lung cancer poses a major challenge and arises partly due to intratumor heterogeneity that defines phenotypically distinct tumor subpopulations. To attain better therapeutic outcomes, it is important to understand the differential therapeutic sensitivities of tumor cell subsets. Epithelial-mesenchymal transition is a biological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase 4
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Mice, Knockout

Share to Neoplasms, Experimental

Share to Organic Cation Transport Proteins

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 34309585
DOI: 10.1172/jci.insight.148392
PMCID: PMC8492319

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.PMID 34309585Read ↗

Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.Semantic proximity Read ↗

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.Semantic proximity Read ↗

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer.Semantic proximity Read ↗

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.Semantic proximity Read ↗

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.Semantic proximity Read ↗

The Role of Mesenchymal Stem Cells in Drug Resistance in Lung NeoplasmsSemantic proximity Read ↗

Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic ManipulationsSemantic proximity Read ↗

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.Semantic proximity Read ↗

MST4 plays dual roles in lung adenocarcinoma by regulating homeostasis of wild-type and mutant p53 protein.Semantic proximity Read ↗

Phenotype-dependent subtyping exposes high MYC activity as a targetable dependency in LuAdSemantic proximity Read ↗

HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.Semantic proximity Read ↗

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.